well yes of course there are lots of unknowns, nothing guaranteed, FILSPARI could be rejected, but so too could DXB200. DXB200 could look better, then again FILSPARI could look better than DXB200. I wasn't thinking the license partners of DXB would pull out though they'd surely reassess their market projections. If DXB200 doesn't get fast approval later this year and has to go through the full trial out to 2 years, that's likely to be well into late 2027/2028 which gives Travere and its partners major time advantage to take the market and make FILSPARI + SGLT2 inhibitor the gold standard which is what I'm hearing is the combination of choice.
DXB Price at posting:
48.0¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)